X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs NATCO PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH NATCO PHARMA STERLING BIOTECH/
NATCO PHARMA
 
P/E (TTM) x -0.4 13.6 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 STERLING BIOTECH   NATCO PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
NATCO PHARMA
Mar-18
STERLING BIOTECH/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs111,080 1.0%   
Low Rs3671 0.5%   
Sales per share (Unadj.) Rs26.8592.1 4.5%  
Earnings per share (Unadj.) Rs-15.0188.4 -7.9%  
Cash flow per share (Unadj.) Rs-5.5206.3 -2.6%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs54.9833.6 6.6%  
Shares outstanding (eoy) m267.8736.90 725.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.31.5 17.5%   
Avg P/E ratio x-0.54.6 -10.0%  
P/CF ratio (eoy) x-1.34.2 -30.0%  
Price / Book Value ratio x0.11.1 12.1%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m1,86232,311 5.8%   
No. of employees `0001.44.8 28.0%   
Total wages/salary Rs m5473,256 16.8%   
Avg. sales/employee Rs Th5,303.34,522.5 117.3%   
Avg. wages/employee Rs Th403.8674.0 59.9%   
Avg. net profit/employee Rs Th-2,959.01,439.0 -205.6%   
INCOME DATA
Net Sales Rs m7,18121,848 32.9%  
Other income Rs m43404 10.5%   
Total revenues Rs m7,22322,252 32.5%   
Gross profit Rs m9479,284 10.2%  
Depreciation Rs m2,543662 384.2%   
Interest Rs m4,377154 2,842.3%   
Profit before tax Rs m-5,9318,872 -66.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,920 -100.2%   
Profit after tax Rs m-4,0076,952 -57.6%  
Gross profit margin %13.242.5 31.0%  
Effective tax rate %32.421.6 149.9%   
Net profit margin %-55.831.8 -175.3%  
BALANCE SHEET DATA
Current assets Rs m14,33521,307 67.3%   
Current liabilities Rs m49,8095,920 841.4%   
Net working cap to sales %-494.070.4 -701.5%  
Current ratio x0.33.6 8.0%  
Inventory Days Days40373 550.7%  
Debtors Days Days171107 160.2%  
Net fixed assets Rs m55,43214,986 369.9%   
Share capital Rs m268369 72.6%   
"Free" reserves Rs m13,93530,353 45.9%   
Net worth Rs m14,70130,760 47.8%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98837,151 199.2%  
Interest coverage x-0.458.6 -0.6%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.6 16.5%   
Return on assets %0.519.1 2.6%  
Return on equity %-27.322.6 -120.6%  
Return on capital %-6.429.3 -21.9%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86010,322 18.0%   
Fx outflow Rs m252,978 0.8%   
Net fx Rs m1,8357,343 25.0%   
CASH FLOW
From Operations Rs m1,7194,636 37.1%  
From Investments Rs m-3,148-11,155 28.2%  
From Financial Activity Rs m1,4266,509 21.9%  
Net Cashflow Rs m-3-18 18.9%  

Share Holding

Indian Promoters % 33.9 52.0 65.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.0 7.8 -  
FIIs % 9.9 16.6 59.5%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 26.0 151.2%  
Shareholders   21,482 25,395 84.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS